TelyRx Holdings Inc. faces a notable downturn as its stock price falls sharply.
TelyRx Holdings Inc. is having a tough trading session, with its stock price dropping by 4.21% to CA$2.50. This decline is raising concerns among investors about the company's recent performance and future prospects.
Advertisement
TelyRx Holdings Inc.
TELY.TO
TELY.TO
TelyRx Holdings Inc.
WealthAwesomeAdvertisement
Market cap
$69.37M
52W high
$4.25
52W low
$2.00
1W change
-1.96%
Analyst Price Targets
Based on analyst covering TELY
Wall Street analysts forecast TELY stock price to rise 140.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.00
+140.0% Upside
Current Price
C$2.50
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on TELY's historical volatility
30-Day Vol
109.4%
Annualized
90-Day Vol
102.2%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$2.09
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$2.36 | C$1.61 – C$3.44 |
| 60 trading days | C$2.22 | C$1.30 – C$3.79 |
| 90 trading days | C$2.09 | C$1.09 – C$4.02 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Keep an eye on TelyRx's financial results and how the market reacts. This recent decline might point to underlying issues that need to be addressed.
TelyRx Holdings Inc. down 4.21% today
The market cap is around CA$69.4 million, reflecting investor sentiment amid the stock's decline.
Bull case
Despite the current downturn, TelyRx reported impressive revenue growth in its latest financial results, increasing from $6.9 million in Q1 2025 to $19.4 million in Q1 2026. This suggests there may be potential for recovery.
Bear case
On the flip side, the company is still facing significant net losses, reporting a net loss of $4.7 million in Q1 2026. This could make investors wary about profitability and sustainable growth.
Advertisement
Recent Performance Overview
In today's trading session, TelyRx Holdings Inc. saw its stock price fall by 4.21%, closing at CA$2.50. This decline is particularly concerning given the company's recent financial results, which showed a significant increase in revenue but also highlighted ongoing net losses.
Financial Results and Market Reaction
TelyRx's latest financial report indicated a revenue increase to $19.4 million in Q1 2026, up from $6.9 million in the same quarter last year. However, the net loss of $4.7 million raises questions about the company's profitability. Investors are reacting to these mixed signals, contributing to the stock's decline. For more details, check out the full financial results and the year-end report.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
